Skip to main content
SpringerLink
Log in

Die Rolle des Stratus-OCT bei der Anti-VEGF-Therapie

Qualitative und quantitative Beurteilung bei neovaskulärer AMD

The role of Stratus OCT in anti-VEGF therapy

Qualitative and quantitative assessment of neovascular AMD

  • Originalien
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die Evaluierung des OCT3 während einer Anti-VEGF-Therapie.

Methodik

Im Rahmen einer AMD bekamen 29 Patienten mit choroidalen Neovaskularisationen insgesamt 3 intravitreale Injektionen mit Ranibizumab. Vor Therapiebeginn, nach 1 Woche sowie nach 1, 2 und 3 Monaten wurden OCT3-Untersuchungen durchgeführt sowie der Visus (ETDRS) ermittelt.

Ergebnisse

Die zentrale Netzhautdicke konnte mit dem OCT3 in 128 von 145 Messungen automatisch quantifiziert werden. Bei Monat 3 fand sich ein im Vergleich zur Baseline deutlicher Zusammenhang zwischen Abnahme der zentralen Netzhautdicke und Zunahme des Visus (84%), jedoch keine statistisch signifikante Korrelation (Pearson =−0,18). Generelle Einschränkungen waren eine inkorrekte Schichtensegmentierung und eine inadäquate Berechnung der zentralen Netzhautdicke bei ausgeprägten retinalen Läsionen.

Schlussfolgerung

Während einer Anti-VEGF-Therapie ermöglicht das OCT3 Dokumentation und Quantifizierung morphologischer Netzhautveränderungen und erlaubt in der Mehrzahl der Fälle auch Rückschlüsse auf funktionelle Verbesserungen. Ein direkter Zusammenhang zwischen Abnahme der Netzhautdicke in der OCT und Zunahme des Visus war jedoch nicht gegeben.

Abstract

Background

The evaluation of OCT3 during anti-VEGF therapy.

Methods

A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months.

Results

The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation.

Conclusion

During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Bressler NM, Bressler SB, Congdon NG et al. (2003) Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 11: 1621–1624

    Google Scholar 

  2. Gohdes DM, Balamurugan A, Larsen BA et al. (2005) Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 3: A17

    Google Scholar 

  3. Klein R, Peto T, Bird A et al. (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 3: 486–495

    Article  Google Scholar 

  4. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 4: 581–611

    Google Scholar 

  5. Lopez PF, Sippy BD, Lambert HM et al. (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 5: 855–868

    Google Scholar 

  6. Otani A, Takagi H, Oh H et al. (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 1: 162–169

    Article  Google Scholar 

  7. Krzystolik MG, Afshari MA, Adamis AP et al. (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 3: 338–346

    Google Scholar 

  8. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 6: 1048–1053

    Article  Google Scholar 

  9. Heier JS, Antoszyk AN, Pavan PR et al. (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113: 642.e1–4

    Article  Google Scholar 

  10. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 3: 361–372

    Google Scholar 

  11. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 14: 1419–1431

    Article  Google Scholar 

  12. Mordenti J, Cuthbertson RA, Ferrara N et al. (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 5: 536–544

    Article  Google Scholar 

  13. Paunescu LA, Schuman JS, Price LL et al. (2004) Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using StratusOCT. Invest Ophthalmol Vis Sci 6: 1716–1724

    Article  Google Scholar 

  14. Gurses-Ozden R, Teng C, Vessani R et al. (2004) Macular and retinal nerve fiber layer thickness measurement reproducibility using optical coherence tomography (OCT-3). J Glaucoma 3: 238–244

    Article  Google Scholar 

  15. Sadda SR, Wu Z, Walsh AC et al. (2006) Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2: 285–293

    Article  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Währinger Gürtel 18–20, 1090, Wien, Österreich

    M. Bolz, M. Ritter, K. Polak, C. Ahlers, C. Hirn, C. Prünte, I. Golbaz & U. Schmidt-Erfurth

  2. Besondere Einrichtung für Medizinische Statistik und Informatik, Institut für Medizinische Statistik, Medizinische Universität Wien, Wien, Österreich

    T. Benesch

Authors
  1. M. Bolz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Polak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Ahlers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Hirn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Prünte
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Golbaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Benesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U. Schmidt-Erfurth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Schmidt-Erfurth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolz, M., Ritter, M., Polak, K. et al. Die Rolle des Stratus-OCT bei der Anti-VEGF-Therapie. Ophthalmologe 105, 650–655 (2008). https://doi.org/10.1007/s00347-007-1639-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-007-1639-1

Schlüsselwörter

Keywords

Search

Navigation